<DOC>
	<DOCNO>NCT00688714</DOCNO>
	<brief_summary>AZD6482 new drug substance aim prevent blood clot may arise atherosclerotic blood vessel cause myocardial infarction stroke . This first study AZD6482 human . The primary aim study evaluate safety tolerability AZD6482 healthy human volunteer . How substance metabolise eliminate body also study . This do comparing effect single ascending dos AZD6482 placebo ( inactive substance ) .</brief_summary>
	<brief_title>Study Investigate Safety Tolerability Single Dose AZD6482</brief_title>
	<detailed_description />
	<criteria>BMI 19.0 30.0 kg/m2 , inclusive body weight 50.0 100.0 kg , inclusive Provision write informed consent Personal family history bleeding disorder , reasonable suspicion vascular malformation , include aneurysm . Acute illness , surgical procedure trauma 2 week preentry visit administration investigational product clinically significant abnormality clinical chemistry , haematology , faeces , urinalysis supine BP pulse Known impair glucose intolerance know suspected GilbertÂ´s syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Antiplatelet</keyword>
</DOC>